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Available online xxxxMany facets of human behaviour are likely to have developed in part due to evolutionary changes in the regula-
tion of neuropeptide and other brain-related genes. This has allowed species-speciﬁc expression patterns and
unique epigenetic modulation in response to our environment, regulating response not only at the molecular
level, but also contributing to differences in behaviour between individuals. As such, genetic variants or epigenet-
ic changes thatmay alter neuropeptide gene expression are predicted to play a role in behavioural conditions and
psychiatric illness. It is therefore of interest to identify regulatory elements that have the potential to drive differ-
ential gene expression. Retrotransposons are mobile genetic elements that are known to be drivers of genomic
diversity, with the ability to alter expression of nearby genes. In particular, the SINE-VNTR-Alu (SVA) class of
retrotransposons is speciﬁc to hominids, and its appearance and expansion across the genome has been associ-
ated with the evolution of numerous behavioural traits, presumably through their ability to confer unique regu-
latory properties at the site of their insertion.We review the evidence for SVAs as regulatory elements, exploring
how polymorphic variation within these repetitive sequences can drive allele speciﬁc gene expression, which
would be associated with changes in behaviour and disease risk through the alteration of molecular pathways
that are central to healthy brain function.
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The movement and insertion of retrotransposable elements across
the genome causes mutation that may result in large-scale alterations
in gene expression and regulation. With their ability to introduce new
splice sites, promoters, and regulatory elements into a locus, active
retrotransposition is a driving force for genomic diversity (Cordaux
and Batzer, 2009, Erwin et al., 2014), and is likely to have contributed
to the species- and tissue-speciﬁc expression patterns that we seend Clinical Pharmacology, The
UK.
t al., SVA retrotransposons as
6.09.006in primates and humans (Robbez-Masson and Rowe, 2015). While
they are often referred to as “jumping genes”, the majority of
retrotransposable elements have over time lost their ability to mobilise
(Brouha et al., 2003, Mills et al., 2007). However, they still containmany
elements that are capable of conferring regulatory properties and may
inﬂuence the genetic architecture and function at the surrounding
loci. In this regard, retrotransposable elements can be considered as ge-
netic elements that may impact the regulation of nearby genes, regard-
less of any further retrotransposition events. It is in this context that
they will herein be considered, and we highlight the importance of
these elements in relation to genes of interest discussed by groups at
the Aberdeen Neuropeptide Conference 2015, in particular the AVP/
Oxytocin locus, as well as the tachykinin receptor TACR3, and voltage
gated ion channels TRPV1/V3.potential modulators of neuropeptide gene expression, Neuropeptides
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Transposable elements (TEs) make up approximately half of the
human genome (Lander et al., 2001), and are broadly divided into two
categories, named class I and class II, based on their method of replica-
tion via a DNA or RNA intermediate. Class II elements include DNA
transposons, which make up around 2% of our genome, and are
known to have beenmobilised as DNA through a cut-and-paste mecha-
nism before losing their ability to mobilise in the human lineage
(Bouuaert and Chalmers, 2010, Hancks and Kazazian, 2012).
Alternatively, class I TEs are mobilised and inserted through a two-
step process that ﬁrst involves transcription from the DNA sequence
to produce an RNA intermediate. This RNA intermediate is then reverse
transcribed into DNA and inserted into a new position in the genome.
Class I TEs can be further divided into LTR and non-LTR families, based
on the presence or absence of long terminal repeats (LTRs) within the
element sequence. LTR retrotransposons include human endogenous
retroviruses (HERVs), which make up around 8% of our genome and
function in gene regulation, often encoding alternative promoters,
resulting in tissue-speciﬁc expression (Belshaw et al., 2004).
Non-LTR retrotransposons include Long Interspersed Nuclear Ele-
ments (LINEs), Short Interspersed Nuclear Elements (SINEs), and
SINE-VNTR-Alus (VNTR = Variable Number Tandem Repeat; SVAs),
and are known to be the most abundant class of mobile element in
the human genome. While the majority of transposable elements have
become inactive throughout the course of evolution, non-LTR
retrotransposons are the only group that are known to remain mobile
and active within the human lineage (Mills et al., 2007).
SVAs are the most recently evolved family of active non-LTR
retrotransposable elements, being present only in the hominid ge-
nomes, with approximately 2700–3000 SVA copies in humans (Lander
et al., 2001, Savage et al., 2013). These non-autonomous elements con-
tain consensus sequences for LINE-1 endonuclease recognition, and rely
directly on active expression of the LINE-1 machinery, ORF1p and
ORF2p, in order to be mobilised in trans (Hancks et al., 2011, Raiz et
al., 2012).
The SVA family of transposable elements can be further divided into
7 subfamilies, named A – F1 in order of age. SVA A is the oldest subfam-
ily in evolutionary terms (~13.6Myrs) and SVAE, F (~3.5 and ~3.2Myrs,
respectively), and F1 the youngest, whilst subfamilies D and B are the
most abundant in the genome, accounting for ~40% and ~15% of the
total number of SVA elements. The youngest subfamilies, SVA E, F, and
F1, are human speciﬁc, and along with SVA D (~9.6 Myrs), are the
only subfamilies that remainpolymorphicwithin thehumanpopulation
(Wang et al., 2005).
Structurally, a canonical SVA is comprised of 5 main components
(Fig. 1), beginning with (1) a simple hexamer repeat of (CCCTCT)n at
the 5′ end, which may be variable in copy number, followed by (2) an
Alu-like region made up of two antisense Alu fragments separated by
a region of intervening sequence, (3) one or two variable number tan-
dem repeat (VNTR) regions, typically with a repeating sequence be-
tween 35 and 50 bp, (4) a SINE region derived from the 3′ LTR of the
retroviral HERV-K10 element, and ﬁnally (5) a 3′ poly-A signal (Wang
et al., 2005). The seventh SVA family, known as F1, lacks the 5′ CCCTCT
hexamer repeat, instead containing a 5′ transduction of exon 1 of the
MAST2 gene (Bantysh and Buzdin, 2009).Fig. 1. Schematic of a canonical SVA structure showing the ﬁve key domains, beginning with a
contains a region of variable number tandem repeats (VNTRs), with older SVAs containing on
VNTR, and a poly-A tail marks the 3′ end of the SVA.
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Over 60% of SVAs in the human genome are located in genes, or
within 10 kb of their ﬂanking sequence (Savage et al., 2013). SVAs are
known to be enriched at high GC and gene dense regions, which may
suggest preferential insertion in areas such as promoters and actively
transcribed regions (Wang et al., 2005). SVAs themselves are generally
around 60% GC, with this potentially exceeding 70%within the VNTR re-
gion (Wang et al., 2005). The deﬁnition of a CpG island is a sequence
over 200 bp with a GC content exceeding 50% and an observed-to-ex-
pected CpG ratio over 60%. As such, SVAs may be simplistically thought
of as mobile CpG islands (Strichman-Almashanu et al., 2002). Indeed,
the ﬁrst exon of MAST2, which has been incorporated into the SVA F1
structure through a 5′ transduction, is deﬁned as a CpG island and has
been conﬁrmed to act as a positive transcriptional regulator in human
germline cells (Zabolotneva et al., 2012). In thisway, SVAsmay positive-
ly or negatively regulate expression of nearby genes by recruiting tran-
scription factors or altering local chromatin structure depending on
epigenetic marks across the element, as has been demonstrated for
human endogenous retroviruses (Fasching et al., 2015), causing a region
to become either accessible or inaccessible to transcriptionalmachinery.
It is known that retrotransposable elements become hypomethylated in
disease states such as cancer (Barchitta et al., 2014, Miousse and
Koturbash, 2015), where primate-speciﬁc retrotransposons are prefer-
entially affected (Szpakowski et al., 2009), and some retrotransposons
become hypomethylated during human ageing (Luo et al., 2014,
Jintaridth and Mutirangura, 2010, Bollati et al., 2009). Thus, changes in
epigenetic marks across SVAs resulting in, for example, inappropriate
reactivation of the element, may contribute to dysregulation of nearby
genes and their related pathways, as has been demonstrated for LINE-
1 elements in cancer (Hur et al., 2014).
Due to their high GC content, SVAs may also be capable of forming
alternative DNA structures which affect transcription, such as G-
quadruplexes (G4) (Kejnovsky et al., 2015). G4 structures form in re-
gions containing multiple short runs of G bases, which form planar tet-
rad structures throughHoogsteen hydrogen bonding and stack together
to form helices (Rhodes and Lipps, 2015). Over 40% of human genes
contain one or more potential G4 sequences in their promoter region
(Huppert and Balasubramanian, 2007), and mutation or stabilisation
of the G4 structure has been shown to modify gene expression both in
vitro and in vivo (David et al., 2016, Shin et al., 2015, Gu et al., 2012,
Wang et al., 2010). Through sequence analysis, our group have shown
that despite accounting for only 0.13% of the total genome, SVAs make
up nearly 2% of DNA across the genome that is predicted to form G4
structures. In particular, the 5′ CCCTCT hexamer repeat in SVAs is likely
to be the most amenable to G4 formation, and, when accounting for
their size, SVAs have the greatest contribution to G4 DNA out of all
other genetic elements (Savage et al., 2013). As the evolutionary age
of the SVA subtypes decreases, the percentage of sequence capable of
quadruplex formation is increased, giving the human-speciﬁc SVA E, F,
and F1 subtypes the most potential to form transcriptional modulatory
G4 structures. This is due in part to the increased copy number of the
CCCTCT hexamer repeat in younger SVA subtypes, and also to the in-
crease in VNTR potential to form quadruplex, as the younger subtypes
contain two VNTRs with a higher GC content, as opposed to one with
lower GC content in the older SVAs. For example, the SVA F1 subtype5′ repeat of the CCCTCT hexamer, followed by an Alu-like structure. The middle of the SVA
e, and younger SVAs containing two tandem repeat regions. A SINE-R region follows the
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the high GC VNTR regions (Savage et al., 2013).
We have demonstrated the regulatory properties of both full length
SVAs as well as their individual components using reporter gene con-
structs both in vitro and in vivo, in cell lines and chick embryo models
(Savage et al., 2013, Savage et al., 2014). For example, the Parkinson's
related gene, PARK7, has a full length human-speciﬁc SVA D located ap-
proximately 8 kb from themajor transcriptional start site. Reporter gene
experiments showed that the PARK7 SVA can positively modulate ex-
pression in vitro, with a truncation lacking the SINE domain showing
the greatest enhancer capability. Individually, the tandem repeat region
of this SVA acted as a negative regulator of transcription, identifying a
range of modulatory effects conferred by the distinct elements in this
composite structure (Savage et al., 2013). Similarly, our analysis of the
primate-speciﬁc SVA D, which lies 10 kb upstream of the FUS gene, ver-
iﬁed the regulatory properties of this SVA in vivo using a chick embryo
model. Again, different components of the SVA displayed different reg-
ulatory properties, with the central VNTR region acting as a positive
transcriptional regulator, whereas the complete SVA acted to decrease
reporter gene expression. GFP imaging studies in the chick embryo re-
vealed activity of the FUS SVA in the developing neural tube (Savage
et al., 2014).
Kim et al. have also demonstrated the capacity of SVAs to act as novel
promoters through bioinformatic analysis of human-speciﬁc insertions
that are expressed as exons in the transcriptome. Although this analysis
would not capture SVAs acting as more distant regulators, Kim et al.
identiﬁed 12 cases in which human-speciﬁc SVA insertions led to the
formation of novel promoters, driving expression of human-speciﬁc
transcripts originating from within the SVA (Kim and Hahn, 2011). For
example, an SVA insertion 5′ to the TBPL2 gene has been shown to act
as a novel promoter for a human-speciﬁc transcript of TBPL2, in which
SVA derived sequence is included as a novel ﬁrst exon. Similarly, an
SVA insertion at intron 19 of the WDR66 gene resulted in expression
of a human-speciﬁc truncated isoform of WDR66, containing exons
20–22 (Kim and Hahn, 2011). SVA insertions have also been shown to
drive expression of novel antisense transcripts, including a human-spe-
ciﬁc SVA insertion at intron 45 of the SYNE2 gene, which acts as a novel
promoter for the expression of six antisense ESTs (Kim andHahn, 2010).
Multiple components of the SVA composite structure are known to
regulate neuropeptide gene expression individually. VNTRs, which are
a major component of SVAs, have been demonstrated to be key neuro-
peptide regulatory domains. For example, the arginine vasopressin 1a
receptor (AVPR1A) contains two upstream VNTRs named RS1 and
RS3. These repetitive regions were originally identiﬁed in the prairie
vole, and polymorphisms were found to be associated with monoga-
mous and non-monogamous behaviour between different species
(Hammock et al., 2005, Hammock and Young, 2002). Tansey et al.
have demonstrated the allele-speciﬁc regulatory effects of both repeti-
tive regions, with the long alleles of both the RS1 and RS3 supporting in-
creased transcription of a reporter gene over the shorter alleles in the
SH-SY5Y neuroblastoma cell line (Tansey et al., 2011). Further studies
have shown that differences in tandem repeat number at the promoter
of AVPR1A contributes to differences in tissue-speciﬁc expression,
resulting in species-speciﬁc receptor distribution across the brain and
contributing to behavioural diversity (Donaldson and Young, 2013). In
humans, variation at the AVPR1A RS1 and RS3 has been associated
with differences in behavioural traits such as pair bonding (Walum et
al., 2008). Variation at these regions is known to interact with environ-
mental factors such as childhood adversity to mediate social behaviour
in adulthood (Liu et al., 2015), and has been shown to correlate with au-
tism spectrumbehaviour in Finnish and Korean populations (Kantojarvi
et al., 2015, Yang et al., 2010).
Similarly, expression of the POMC gene in both the human and
mouse hypothalamus is co-ordinated by the action of two distal regula-
tory elements, named nPE1 and nPE2, which act as neuronal enhancers
(de Souza et al., 2005). By comparing genomes from multiple species,Please cite this article as: Gianfrancesco, O., et al., SVA retrotransposons as
(2016), http://dx.doi.org/10.1016/j.npep.2016.09.006Santangelo et al. demonstrated that nPE2 originated from a SINE
retrotransposon insertion at this locus in the evolutionary lineage lead-
ing tomammals, thereby conferringdistinct regulatory properties to the
mammalian POMC gene in hypothalamic neurons (Santangelo et al.,
2007). Kuehnen et al. have also demonstrated the regulatory effects of
Alu element insertion into the POMC gene through evolution. The
human intron 2 of POMC contains three Alu insertions and the CpG is-
land at this region is hypermethylated. A similar pattern of hypermethy-
lation at this region is seen in chimpanzees, who also have Alu
insertions at the POMC intron 2. However, in the mouse and in more
distant primates such as lemurs, no Alu insertions are present in
POMC intron 2 and consequently little to nomethylation is found across
this region. This suggests that the insertion of retrotransposons into this
neuropeptide gene through evolution has resulted in species-speciﬁc
methylation patterns which are likely to result in altered expression of
POMC in higher primates (Kuehnen et al., 2012).
As SVA are composite structures which include SINE, VNTR and Alu
sequences, their presence in genic regions may inﬂuence transcription
in a manner similar to the above. Observation of neuropeptide-related
gene loci revealed SVA insertions in the upstream regions of the
tachykinin TACR3 receptor (Fig. 2a), the oxytocin encoding OXT (Fig.
2b), and between the cation channel TRPV1 and TRPV3 genes (Fig.
2c), with the latter having an extensive literature onmodulation of neu-
ropeptide function and release. Both TACR3 and OXT have a chimp- and
human-speciﬁc SVA B beginning less than 3 kb and 8 kb upstream of
their respective promoters, which may have conferred distinct regula-
tion of tachykinin receptor 3 and oxytocin in humans and chimpanzees.
Vanilloid receptors such as TRPV1 and TRPV3 are also of interest in un-
derstanding neuropeptide function, as their activation leads to release
of substance P, therefore demonstrating a close relationship between
the two systems in many areas of neuronal signalling (Keszthelyi et
al., 2013). The TRPV1/V3 genes are separated by approximately 8 kb be-
tween the 5′ end of TRPV3 and the 3′ end of TRPV1, and this region con-
tains a human-speciﬁc SVA D. The SVA at this locus is less than 6 kb
upstream of the TRPV3 transcriptional start site, and immediately adja-
cent to the end of TRPV1, thus allowing it to potentially modulate the
expression of both genes. In a similar manner, the SVA upstream of
the OXT gene could potentially regulate the nearby AVP gene at this
locus. We hypothesise that these hominid-speciﬁc retrotransposons
would therefore impart speciﬁc regulatory properties upon these
genes that may allow for evolutionary changes in their tissue-speciﬁc
or stimulus inducible regulation.
4. The polymorphic nature of SVAs
SVAs are considered to be the most polymorphic elements in the
human genome, not just in structure but also for their presence or ab-
sence (Bennett et al., 2004). Although mobile genetic elements are
often stringently repressed to prevent deleterious changes to the cell's
genome through further mobilisation and insertion (Yang and Wang,
2016), active retrotransposition is known to occur during normal differ-
entiation of neuronal stem cells, and in adult neurogenesis (Coufal et al.,
2009, Muotri et al., 2009). As such, many of our brain cells contain
unique retrotransposon insertions. Although the exact rate is currently
an area of controversy (Upton et al., 2015, Hazen et al., 2016, Evrony et
al., 2016), all groups agree that active mobilisation of retrotransposons
occurs in the brain. Higher estimates suggest that each hippocampal
neuron contains approximately 13.7 new somatic LINE-1 insertions on
average, which are highly enriched at brain-related gene loci (Upton
et al., 2015), however differences in the estimated rates may result
from differing sensitivities of the techniques used, and may also differ
by cell type.
The SVA structure itself is composed of multiple repetitive domains,
each of which may contribute to polymorphic variation in the SVA due
to differences in copy number. Within the aforementioned PARK7
SVA, we identiﬁed three common variants of the CCCTCT hexamerpotential modulators of neuropeptide gene expression, Neuropeptides
Fig. 2. Schematic of the TACR3, OXT, and TRPV1/V3 genes, displaying the positions and evolutionary conservation of SVAs at these loci. (a) The TACR3 gene has a human- and chimp-
speciﬁc SVA B beginning less than 3 kb upstream of the transcriptional start site. (b) Similarly, a human- and chimp- speciﬁc SVA B lies less than 8 kb upstream of the OXT
transcriptional start site. (c) Finally, a human-speciﬁc SVA D is present within the intervening 8 kb of sequence separating the TRPV1 and TRPV3 genes, with the SVA residing
approximately 6 kb upstream of TRPV3 and directly adjacent to the 3′ end of TRPV1. We hypothesise that insertion of SVAs at these loci may have altered regulation of neuropeptide
related gene expression during hominid evolution.
4 O. Gianfrancesco et al. / Neuropeptides xxx (2016) xxx–xxxVNTR, with 7, 10, or 13 copies of the repeat. Similarly, we have shown
variation in length in the terminal poly-A stretch in other
retrotransposable elements (Payton et al., 2016). However, the most
likely region for copy number variation is the large central VNTR do-
main, which we have shown to be polymorphic in both the PARK7
SVA and the FUS SVA. We identiﬁed three distinct alleles of the central
VNTR in the PARK7 SVA and two alleles in the FUS SVA (Savage et al.,
2013, Savage et al., 2014).
5. Summary
Overall, our work suggests that SVA elements can alter gene expres-
sion through their capacity for local transcriptional and epigeneticmod-
ulation.We hypothesise that SVA insertions at theOXT/AVP, TACR3, and
TRPV1/V3 loci, all genes discussed at the Aberdeen Neuropeptide Con-
ference 2015, have contributed to the evolution of species-speciﬁc reg-
ulation and expression of these genes in humans and other primates,
allowing the evolution of higher cognitive and social functioning, as
well as variation at these loci acting in combination with our environ-
ment to modulate human behaviour. Their high GC content may allow
them to act through a similar mechanism to CpG islands, altering the
transcriptional availability of a locus depending on epigenetic markersPlease cite this article as: Gianfrancesco, O., et al., SVA retrotransposons as
(2016), http://dx.doi.org/10.1016/j.npep.2016.09.006across the element, as demonstrated for the Alu retrotransposon in
the POMC gene. Similarly, their high G content means that SVAs have
the potential to form alternative DNA structures such as G-quadruplex,
which is known to alter transcription and facilitate enhancer-promoter
interactions to regulate gene expression across a locus. Variation within
SVA elements also provides an additional mechanism to drive differen-
tial gene expression through allele-speciﬁc transcription factor binding
and identiﬁes them as potential biomarkers for disease. The presence of
SVAs at neuropeptide gene loci points to a retrotransposon-mediated
evolutionary mechanism which may have contributed to the develop-
ment of human behavioural traits.
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